Literature DB >> 10521063

Significance of cytoreductive surgery including bowel resection for patients with advanced ovarian cancer.

M Shimada1, J Kigawa, Y Minagawa, T Irie, M Takahashi, N Terakawa.   

Abstract

The aim of this study was to determine the significance of bowel resection in advanced ovarian cancer. A total of 64 women with stage IIIc or IV epithelial ovarian cancer, who consecutively received primary treatment between 1991 and 1995, were entered in this prospective study. The outcome of the patients undergoing bowel resection was evaluated. Thirty-nine patients underwent cytoreductive surgery at initial surgery. Of them, 16 patients could undergo optimal operation without bowel resection. Twenty-three patients received bowel resection at initial surgery. Of these 23 patients, 16 underwent optimal operation and 7 did not. Among 25 patients judged as inoperable cases at initial surgery, 21 responded to chemotherapy and underwent second surgery. Of 21 patients receiving second surgery, 15 underwent optimal operation (7 without bowel resection and 8 with bowel resection). The 3-year survival rate for 24 patients undergoing optimal operation with bowel resection (46.8%) was not significantly different from that for 23 patients without bowel resection (59.1%). Postoperative complications were seen in 8 patients (21.6%) of the patients receiving bowel resection and 3 (13.0%) of those without bowel resection. Cytoreductive surgery including bowel resection is effective for an improvement of the survival in patients with advanced ovarian cancer, if an optimal operation can be performed.

Entities:  

Mesh:

Year:  1999        PMID: 10521063     DOI: 10.1097/00000421-199910000-00012

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  6 in total

Review 1.  Radical surgery in ovarian cancer.

Authors:  Deepa Maheswari Narasimhulu; Fady Khoury-Collado; Dennis S Chi
Journal:  Curr Oncol Rep       Date:  2015-04       Impact factor: 5.075

2.  Computed tomographic enterography (CTE) in evaluating bowel involvement in patients with ovarian cancer.

Authors:  Xiao-Mei Zhang; Xin-Yu Zhang; Yue-Xi Liu; Ruo-Nan Li; Yong-Mei Li; Hua Linghu
Journal:  Abdom Radiol (NY)       Date:  2022-04-05

3.  Clinical Phenotypes of Tumors Invading the Rectosigmoid Colon Affecting the Extent of Debulking Surgery and Survival in Advanced Ovarian Cancer.

Authors:  Soo Jin Park; Jaehee Mun; Eun Ji Lee; Sunwoo Park; Sang Youn Kim; Whasun Lim; Gwonhwa Song; Jae-Weon Kim; Seungmee Lee; Hee Seung Kim
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

4.  Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT).

Authors:  Fabian Trillsch; Jan David Ruetzel; Uwe Herwig; Ulrike Doerste; Linn Woelber; Donata Grimm; Matthias Choschzick; Fritz Jaenicke; Sven Mahner
Journal:  J Ovarian Res       Date:  2013-07-09       Impact factor: 4.234

5.  Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study.

Authors:  Upasana Baruah; Debabrata Barmon; Amal Chandra Kataki; Pankaj Deka; Munlima Hazarika; Bhargab J Saikia
Journal:  Indian J Med Paediatr Oncol       Date:  2015 Jan-Mar

Review 6.  Advanced ovarian cancer.

Authors:  M E van der Burg
Journal:  Curr Treat Options Oncol       Date:  2001-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.